Get the Daily Brief
Latest Biotech News
Grail files Galleri for FDA PMA: large prospective datasets underpin bid
Grail submitted a premarket approval application to the FDA for its Galleri multi‑cancer early detection test, relying on performance and safety data from more than 25,000 participants in the...
DeepMind’s AlphaGenome: long‑context model decodes regulatory variants
DeepMind published AlphaGenome, a long‑sequence DNA model that predicts regulatory effects of non‑coding variants across up to one million base pairs. The Nature paper shows the model can infer...
Beckman–Automata tie-up: Danaher strategic backing, $45M Series C to scale lab automation
Beckman Coulter Life Sciences and Automata announced a strategic partnership integrating Beckman liquid‑handling and analytic instrumentation into Automata’s LINQ AI‑ready automation ecosystem;...
Thermo Fisher raises 2026 outlook: mid‑single digit growth expected after strong quarter
Thermo Fisher reported stronger‑than‑expected Q4 results and gave 2026 guidance calling for roughly 4–6% revenue growth, driven by life‑science solutions and laboratory products. The company...
AstraZeneca’s China bet: $1.2B CSPC obesity pact and $15B China push
AstraZeneca agreed a $1.2 billion upfront licensing deal with China’s CSPC and outlined a sweeping China strategy, doubling down on obesity and metabolic medicines. The CSPC pact gives AZ rights...
Illumina snaps up SomaLogic: proteomics meets sequencing
Illumina completed its acquisition of SomaLogic and related assets from Standard BioTools, paying $350 million in cash and taking on near‑term milestones and royalties. The deal folds SomaLogic’s...
FDA backs NanoMosaic: AMT designation for gene therapy QC
The FDA granted NanoMosaic an Advanced Manufacturing Technology (AMT) designation for its Nanoneedle/Tessie platform that measures AAV vector genome integrity and capsid titers during gene therapy...
Lab automation scales: Beckman pairs with Automata; Automata nets $45M
Beckman Coulter Life Sciences announced a strategic partnership with Automata to integrate Beckman liquid‑handling, genomic and cell‑analysis instruments into Automata’s AI‑ready LINQ automation...
Quince’s Phase‑3 failure stalls eDSP program — company written down
Quince Therapeutics announced top‑line failure of its pivotal Neat Phase III trial testing dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) for ataxia‑telangiectasia...
Repertoire inks big autoimmune pact: Lilly deal validates Decode platform
Repertoire Immune Medicines struck a major partnership with Eli Lilly worth up to approximately $1.92 billion to develop tolerizing therapies for autoimmune diseases using Repertoire’s Decode...
Tenpoint wins FDA nod for dual‑agent presbyopia drop and secures $235M
The FDA approved Tenpoint Therapeutics’ Yuvezzi, the first dual‑agent eye drop for presbyopia combining carbachol and brimonidine. Tenpoint also closed $235 million in combined equity and debt...
Lilly builds capacity for obesity era: $3.5B Lehigh Valley factory
Eli Lilly unveiled plans for a $3.5 billion manufacturing facility in Lehigh Valley, Pennsylvania, intended to produce its next‑generation obesity injectable retatrutide and other weight‑loss...
DeepMind’s AlphaGenome maps non‑coding DNA: regulatory variant predictions
DeepMind published AlphaGenome, a large sequence model designed to predict the functional effects of variants across the non‑coding 'dark' genome. The model takes long DNA contexts (up to one...
Ultragenyx resubmits Sanfilippo AAV therapy: FDA re‑filing after rejection
Ultragenyx resubmitted its biologics license application for UX111, an AAV gene therapy candidate for Sanfilippo syndrome type A, after the FDA rejected the original filing last summer. The...
AstraZeneca vows $15B China push—R&D and manufacturing expansion
AstraZeneca announced a multi-billion-dollar expansion in China and struck a high-value collaboration to broaden its obesity and diabetes pipeline. The company committed more than $15 billion...
Lilly builds $3.5B factory—retatrutide and next-gen obesity drugs slated
Eli Lilly disclosed a $3.5 billion manufacturing investment to produce its next-generation obesity injectables, including retatrutide, at a new Lehigh Valley facility. The plant will house both...
Tenpoint wins FDA nod—dual-agent presbyopia drop cleared and $235M secured
Tenpoint Therapeutics won U.S. FDA approval for Yuvezzi, a combination eye drop for adult presbyopia, and announced financing to support commercialization. The FDA clearance makes Yuvezzi the...
Illumina closes SomaLogic buy—proteomics and CLIA lab fold into NGS leader
Illumina completed its acquisition of SomaLogic and related assets from Standard BioTools for $350 million in cash plus contingent payments, expanding Illumina’s footprint in proteomics and...
NanoMosaic wins FDA AMT—nanoneedle QC platform fast-tracked for gene therapy
NanoMosaic secured an FDA Advanced Manufacturing Technology (AMT) designation for its Nanoneedle/Tessie platform, marking regulatory recognition of a high‑throughput QC assay for AAV gene therapy...
Beckman Coulter and Automata pair up—Danaher joins Automata’s Series C
Beckman Coulter Life Sciences announced a strategic partnership with lab‑automation firm Automata to integrate liquid‑handling and genomics instruments into Automata’s LINQ automation ecosystem;...